REPL
NASD Replimune Group, Inc.$13.00 ↑ +0.00 (+0.00%) Trading Up from the previous close of $13.00
- YTD change
- +33.74%
- vs 20-day SMA
- -4.49%
- vs 200-day SMA
- +46.35%
Price ranges
Price & Performance
+5.80 (+80.56%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 76.3% away from all-time highs of $54.85
- REPL is up 34% since the beginning of the year
- REPL is up 210% over the past 12 months
- REPL is down 15% over the past 1 month
- 26% of all REPL investors are betting against REPL
REPL reads neutral: price sits above one of the two key moving averages, the 12-month move is +210.3%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -3.49%
- vs 8-day SMA
- +1.08%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.